---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007365"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T05:10:11.414757+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncotelic publishes study showing TGF-β2 predicts poor survival in DIPG; OT-101 protocol accepted by NIHR

## Summary
- Publication in Cancers shows high intra-tumor TGF-β2 level predicts poor survival in pediatric brainstem cancer (DIPG).
- TGFβ1 and TGFβ3 isoforms are also predictive; OT-101 is the only TGFβ2 inhibitor in late clinical development.
- Clinical study protocol for OT-101 in pediatric brainstem cancer accepted onto UK NIHR portfolio.
- CEO states targeting TGFβ2 could rectify previous clinical failures such as bintrafusp alfa.

## SEC filing metadata
- accession: 0001493152-23-007365
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315223007365/0001493152-23-007365-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315223007365/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007365
- JSON: https://secwatch.observer/filing/0001493152-23-007365.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007365.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.